Alnylam Pharmaceuticals, Inc. (ALNY) stock forecast & analysis
165.00
NasdaqGS · USDDelayed by 15 minutes
Down: -9.00, -5.2%
165.88Up: +0.88, +0.5%
1 analysis
Latest analysis: · verdict locked
- Open
- 172.70
- Previous close
- 174.00
- Day range
- 163.30 – 180.61
- 52-week range
- 163.30 – 479.79
- Volume (shares)
- 7.00M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 133.94M
- P/E ratio
- 8.33
- Dividend yield
- 0.00%
- Beta
- 0.27
- Market cap
- 22.10B
Market Scanner’s AI analysis of Alnylam Pharmaceuticals, Inc. (ALNY), updated November 2026: ALNY's stock price experienced a significant decline, falling below key moving averages and approaching its 52-week low.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Alnylam Pharmaceuticals, Inc. (ALNY) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
ALNY's stock price experienced a significant decline, falling below key moving averages and approaching its 52-week low.
Recent analyses covered a sharp, volume-driven price drop in ALNY, pushing the stock significantly below its 50-day and 200-day moving averages. The stock is now trading near its 52-week low. The analyses noted a lack of specific news catalysts or fundamental drivers for the recent price action.
ALNY news & sentiment
News reports provided no usable information regarding Alnylam Pharmaceuticals for the past week. Social media sentiment could not be assessed due to a lack of relevant news or company-specific discussion.
ALNY technical picture
ALNY's stock experienced a sharp, volume-driven decline, pushing it significantly below its 50-day and 200-day moving averages. The price action is currently oversold, trading near its 52-week low, but no reversal signal has yet been identified.
Fundamentals
The analysis covered Alnylam Pharmaceuticals' valuation, noting its current price relative to its 52-week range and moving averages. Trailing and forward P/E multiples were also discussed.
Factors discussed — upside
- Stock is oversold
- Price is 1.0% above 52-week low
Factors discussed — risks
- Significant price decline over seven and thirty days
- Price is 30.2% below 50-day SMA
- Price is 42.2% below 200-day SMA
- No reversal signal identified
- Technical price action
- Moving averages
- Valuation metrics
Summary updated .
ALNY technical indicators
Common technical indicators for ALNY, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 236.49 | Price below |
| 10-day exponential moving average | 209.00 | Price below |
| Relative strength index (14-day) | 22.05 | Oversold |
| MACD line (12/26/9) | -11.2565 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 185.95 – 257.33 | Price below the lower band |
Analyses
Recent ALNY.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-01 ALNY.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Alnylam Pharmaceuticals, Inc.?
- The stock is currently oversold and trading near its 52-week low, suggesting potential for a rebound.
- What are the risks for Alnylam Pharmaceuticals, Inc.?
- The company's stock has experienced a significant price decline, falling well below key moving averages and showing no immediate reversal signal. Risks include the stock's distance from its 50-day and 200-day simple moving averages.
- Is Alnylam Pharmaceuticals, Inc. bullish or bearish?
- Recent AI analyses of Alnylam Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: The stock is currently oversold and trading near its 52-week low, suggesting potential for a rebound. Discussed risks: The company's stock has experienced a significant price decline, falling well below key moving averages and showing no immediate reversal signal. Risks include the stock's distance from its 50-day and 200-day simple moving averages. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Alnylam Pharmaceuticals, Inc.?
- News reports provided no usable information regarding Alnylam Pharmaceuticals for the past week. Social media sentiment could not be assessed due to a lack of relevant news or company-specific discussion.
- How does Market Scanner analyse Alnylam Pharmaceuticals, Inc.?
- Every analysis of Alnylam Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Alnylam Pharmaceuticals, Inc.?
The stock is currently oversold and trading near its 52-week low, suggesting potential for a rebound.
What are the risks for Alnylam Pharmaceuticals, Inc.?
The company's stock has experienced a significant price decline, falling well below key moving averages and showing no immediate reversal signal. Risks include the stock's distance from its 50-day and 200-day simple moving averages.
Is Alnylam Pharmaceuticals, Inc. bullish or bearish?
Recent AI analyses of Alnylam Pharmaceuticals, Inc. examined factors on both sides. Discussed upside: The stock is currently oversold and trading near its 52-week low, suggesting potential for a rebound. Discussed risks: The company's stock has experienced a significant price decline, falling well below key moving averages and showing no immediate reversal signal. Risks include the stock's distance from its 50-day and 200-day simple moving averages. These are descriptive observations, not a recommendation.
What is the latest sentiment on Alnylam Pharmaceuticals, Inc.?
News reports provided no usable information regarding Alnylam Pharmaceuticals for the past week. Social media sentiment could not be assessed due to a lack of relevant news or company-specific discussion.
How does Market Scanner analyse Alnylam Pharmaceuticals, Inc.?
Every analysis of Alnylam Pharmaceuticals, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- claude-medium-v2
Run a fresh ALNY.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.